To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Atosiban (Tractocile® or Antocin®, RWJ 22164) is an inhibitor of the hormones oxytocin and vasopressin, and is used intravenously in premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. It was developed by Ferring Pharmaceuticals in Sweden and first reported in the literature in 1985.
Additional recommended knowledge
Chemically, it is a modified form of oxytocin that inhibits the action of this hormone on the uterus, leading to a cessation of contractions. It is therefore a tocolytic.
A 2005 systematic review by the Cochrane Collaboration showed that while atosiban had less side-effects than alternative drugs (such as ritodrine), it was no better than placebo in the major outcomes, and in one study showed worse neonatal outcomes. The reviewers suggest nifedipine may be more promising.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Atosiban". A list of authors is available in Wikipedia.|